Itacitinib

N/A

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameItacitinib
Drug Alias NameItacitinib adipate伊西替尼伊他替尼INCB-039110-adipateINCB-39110 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsPlaque psoriasisSolid tumoursCytokine Release Syndrome +[51] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[28] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Biosciences Uk LtdWashington University School Of MedicineIncyte Corp +[8] 
Inactive CompaniesUtah State UniversityColumbia UniversityScri Development Innovations Llc +[4] 
Active IndicationsCytokine Release SyndromePrimary MyelofibrosisMyeloproliferative Disorders +[26] 
Inactive IndicationsPlaque psoriasisSolid tumoursGraft vs Host Disease +[25] 

Other Information

ATC CodeN/A
Related LinksN/A